Wczytywanie spółki
Just reported
From Protagonist Therapeutics's results release of 5 listopada 2026; its quarterly report has since been filed.
Actual
274,4M USD
+29% q/q
Guided
—
No guide given
Actual
3,07 USD
+34% q/q
Guided
—
No guide given
Actual
218,3M USD
+38% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Protagonist Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now AIcotyde (icotrokinra)
An oral peptide medicine that blocks the interleukin-23 receptor, a part of the immune system involved in plaque psoriasis. It is approved in the United States for plaque psoriasis and is licensed to Janssen.
Rusfertide
An injected medicine that imitates hepcidin, a natural hormone that regulates iron. It is being reviewed by U.S. regulators as a treatment for polycythemia vera, a rare disease in which the body makes too many red blood cells.
PN-881
An oral peptide medicine that blocks interleukin-17, an immune-system signal involved in inflammatory skin diseases. It is being studied as a possible treatment for psoriasis and related conditions.
PN-477
A peptide designed to activate the glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon receptors. It is being developed for obesity in oral and injectable forms.
PN-458
A peptide designed to activate the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors. It is being developed for obesity in oral and injectable forms.
PN-8047
An oral small-molecule medicine designed to imitate hepcidin and regulate iron. It is being developed as a possible treatment for polycythemia vera.
Pełne sprawozdania finansowe →
Protagonist discovers and develops medicines, including peptide drugs made from short chains of amino acids. It licenses Icotyde to Janssen, part of Johnson & Johnson, which is responsible for its development and commercialization; Protagonist can receive milestone payments and royalties on sales. Takeda has the worldwide rights to develop and commercialize rusfertide, while Protagonist also advances medicines of its own for immune diseases, blood disorders and obesity.
Zbudowane z własnych raportów spółki Protagonist Therapeutics, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
Protagonist licenses medicines for psoriasis and a rare blood disorder to drug companies, which pay milestone fees and royalties, while developing treatments for obesity.
Grade A+
Pasek pod ceną pokazuje ocenę w każdym dniu, wyliczoną wyłącznie z dokumentów, które były wtedy już publiczne.
Pokazujemy 2 z 27 kwartałów historii ocen spółki Protagonist Therapeutics, Inc.. Pozostałe 25 sięgają do marzec 2019.
